Clinical Trials Browser

Phase 2 × OTHER × Basiliximab × Clear all

NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT02366728 2023-06-08

ELEVATE

Phase 2 Completed

64 enrolled 17 charts

Glioblastoma

NCT04337593 2020-04-07

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Phase 2 Completed

17 enrolled 9 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis